At 5 February 2019, the European Hematology Association and the HARMONY Alliance are organizing the 2nd EHA-HARMONY KOL meeting. The objective of this meeting is to discuss the results of current projects, talk about the newly proposed projects and align on the outcome definition initiative of WP2. Invited to this meeting are the HARMONY Key Opinion Leaders of the 7 Hematological Malignancies Disease Groups.
HARMONY focusses on Acute lymphoblastic leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Myelodysplastic Syndromes, Non-Hodgkins Lymphoma, Multiple Myeloma and Pediatric Hematologic Malignancies. Read more about each of the 7 diseases >.
The HARMONY KOLs are all partners of the HARMONY Alliance.
Receive the latest news. Click here to subscribe!
Public-private partnership for Big Data in Hematology
HARMONY and HARMONY PLUS are funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. Funding is received from the IMI 2 Joint Undertaking and is listed under grant agreement for HARMONY No. 116026 and grant agreement for HARMONY PLUS No. 945406. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
HARMONY Coordination Office
Institute of Biomedical Research of
Salamanca (IBSAL)
Salamanca, Spain
HARMONY Communications
European Hematology Association (EHA)
The Hague, The Netherlands
